Lexaria Bioscience Corp.
LEXX · NASDAQ
5/31/2025 | 2/28/2025 | 11/30/2024 | 8/31/2024 | |
|---|---|---|---|---|
| Market Cap | $18,664 | $25,743 | $34,671 | $51,298 |
| - Cash | $4,592 | $6,469 | $8,078 | $6,500 |
| + Debt | $117 | $124 | $131 | $137 |
| Enterprise Value | $14,189 | $19,397 | $26,723 | $44,935 |
| Revenue | $174 | $174 | $184 | $84 |
| % Growth | 0% | -5.4% | 119% | – |
| Gross Profit | $174 | $174 | $181 | $84 |
| % Margin | 100% | 100% | 98.5% | 100% |
| EBITDA | -$3,719 | -$2,749 | -$2,658 | -$2,202 |
| % Margin | -2,137.6% | -1,579.7% | -1,444.9% | -2,621.4% |
| Net Income | -$3,789 | -$2,713 | -$2,704 | -$2,185 |
| % Margin | -2,177.6% | -1,559.3% | -1,470% | -2,600.9% |
| EPS Diluted | -0.21 | -0.15 | -0.16 | -0.17 |
| % Growth | -40% | 6.3% | 5.9% | – |
| Operating Cash Flow | -$3,584 | -$1,498 | -$2,726 | -$1,892 |
| Capital Expenditures | $0 | $0 | -$25 | -$70 |
| Free Cash Flow | -$3,584 | -$1,498 | -$2,726 | -$1,961 |